Biologics registers in RA: methodological aspects, current role and future applications

Elena Nikiphorou, Maya Buch, Kimme Hyrich

Research output: Contribution to journalComment/debatepeer-review


The beginning of the 21st century saw a biopharmaceutical revolution in the treatment of inflammatory rheumatic diseases, particularly rheumatoid arthritis. The fast-evolving use of biologic therapies highlighted the need to develop registers at national and international levels with the aim of collecting long-term data on patient outcomes. Over the past 15 years, many biologics registers have contributed a wealth of data and provided robust and reliable evidence on the use, effectiveness and safety of these therapies. The unavoidable challenges posed by the continuous introduction of new therapies, particularly with regard to understanding their long-term safety, highlights the importance of learning from experience with established biologic therapies. In this Perspectives article, the role of biologics registers in bridging the evidence gap between efficacy in clinical trials and real-world effectiveness is discussed, with a focus on methodological aspects of registers, their unique features and challenges and their role going forward.
Original languageEnglish
Pages (from-to)503-510
JournalNature Reviews Rheumatology
Issue number8
Early online date1 Jun 2017
Publication statusPublished - 2017


Dive into the research topics of 'Biologics registers in RA: methodological aspects, current role and future applications'. Together they form a unique fingerprint.

Cite this